Log In
BCIQ
Print this Print this
 

PD-1/PD-L1+P1101

  Manage Alerts
Collapse Summary General Information
Company PharmaEssentia Corp.
DescriptionPD-1/PD-L1 antibody immunotherapy with interferon
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLiver cancer
Indication DetailsTreat hepatocellular carcinoma (HCC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today